Case Analysis

Case analysis

Please FOLLOW this format/outline for your case analysis:

A) Identification of the Problem, Main Issue, OR Learning Point of the Case

B) Situation Analysis

C) Recommendations and/or Conclusions

CASE GUIDE QUESTIONS: (to help with your analysis)

1) As CEO of a leading pharmaceutical firm, how do you respond to Dr. Margaret Chan’s (Director-General of the WHO) statements that the pharmaceutical industry is primarily “profit-driven” and had failed to invest in the development of a vaccine or cure for Ebola?

2) You are a shareholder of a pharmaceutical firm that announced its new investment to develop an Ebola vaccine and that as a result, your dividend would be reduced, would you support or not support the firm’s decision to spend your money to combat Ebola? Explain your answer.

3) Take the role of a US government official. What would be your recommendations to incentivize pharmaceutical firms to develop an Ebola vaccine?

Answer preview

Developing a cure or a vaccine for Ebola requires a multi-sectoral collaboration as it is a capital intensive project. My recommendations would be in establishing a fund that pharmaceutical firms can get from the governments to help further their efforts. It would also be of significant value to sponsor medics to study and research more about Ebola and other diseases (Wilkinson & Leach, 2015). This would mean creating an always set team in case of any outbreaks in the future. In helping to minimize strategic challenges that pharmaceutical firms face, I would also sponsor a bill to the Senate that will require pharmaceutical firms to commit a certain amount of resources to research and development. It would also be important to come up with a model that will ensure collaboration of pharmaceutical firms towards combining their resources, synergy, and agendas. This will not only enable the governments to incentivize the companies but will also create an enabling environment to other global bodies like the World

[1289 Words]

Case Analysis
Scroll to Top